S&P 500   2,997.81 (+0.27%)
DOW   27,022.22 (+0.07%)
QQQ   193.36 (+0.17%)
AAPL   234.13 (-0.11%)
FB   189.48 (-0.04%)
MSFT   139.36 (-0.75%)
AMZN   1,788.67 (+0.63%)
CGC   19.97 (+1.22%)
NVDA   193.26 (-0.49%)
MU   45.39 (+0.51%)
GE   9.09 (+2.14%)
AMD   31.06 (+0.81%)
T   37.69 (-0.26%)
NFLX   299.47 (+4.61%)
BAC   30.23 (+0.20%)
DIS   133.27 (+1.84%)
S&P 500   2,997.81 (+0.27%)
DOW   27,022.22 (+0.07%)
QQQ   193.36 (+0.17%)
AAPL   234.13 (-0.11%)
FB   189.48 (-0.04%)
MSFT   139.36 (-0.75%)
AMZN   1,788.67 (+0.63%)
CGC   19.97 (+1.22%)
NVDA   193.26 (-0.49%)
MU   45.39 (+0.51%)
GE   9.09 (+2.14%)
AMD   31.06 (+0.81%)
T   37.69 (-0.26%)
NFLX   299.47 (+4.61%)
BAC   30.23 (+0.20%)
DIS   133.27 (+1.84%)
Log in

Chembio Diagnostics Stock Price, News & Analysis (NASDAQ:CEMI)

$5.76
+0.23 (+4.16 %)
(As of 10/17/2019 11:42 AM ET)
Today's Range
$5.46
Now: $5.76
$5.87
50-Day Range
$4.99
MA: $6.02
$7.13
52-Week Range
$4.39
Now: $5.76
$9.90
Volume14,186 shs
Average Volume49,144 shs
Market Capitalization$101.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.41 million
Book Value$1.94 per share

Profitability

Net Income$-7,870,000.00

Miscellaneous

Employees295
Market Cap$101.20 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.


Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.03. The firm earned $9.59 million during the quarter, compared to analyst estimates of $8.65 million. Chembio Diagnostics had a negative return on equity of 39.62% and a negative net margin of 32.95%. View Chembio Diagnostics' Earnings History.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Chembio Diagnostics.

What guidance has Chembio Diagnostics issued on next quarter's earnings?

Chembio Diagnostics updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $36-40 million, compared to the consensus revenue estimate of $37.75 million.

What price target have analysts set for CEMI?

3 equities research analysts have issued 12-month price objectives for Chembio Diagnostics' shares. Their predictions range from $9.00 to $10.00. On average, they expect Chembio Diagnostics' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 64.9% from the stock's current price. View Analyst Price Targets for Chembio Diagnostics.

What is the consensus analysts' recommendation for Chembio Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chembio Diagnostics.

Has Chembio Diagnostics been receiving favorable news coverage?

News stories about CEMI stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chembio Diagnostics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Chembio Diagnostics.

Are investors shorting Chembio Diagnostics?

Chembio Diagnostics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 163,200 shares, an increase of 11.6% from the August 30th total of 146,200 shares. Based on an average daily volume of 44,400 shares, the days-to-cover ratio is presently 3.7 days. Approximately 1.1% of the shares of the stock are short sold. View Chembio Diagnostics' Current Options Chain.

Who are some of Chembio Diagnostics' key competitors?

What other stocks do shareholders of Chembio Diagnostics own?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
  • Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
  • Mr. David A. Gyorke, Sr. VP & COO (Age 59)

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (1.73%) and Roubaix Capital LLC (1.50%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, John Gary Potthoff, Neil A Goldman and Robert Passas. View Institutional Ownership Trends for Chembio Diagnostics.

Which institutional investors are buying Chembio Diagnostics stock?

CEMI stock was purchased by a variety of institutional investors in the last quarter, including Roubaix Capital LLC and Ingalls & Snyder LLC. Company insiders that have bought Chembio Diagnostics stock in the last two years include John Gary Potthoff, Neil A Goldman and Robert Passas. View Insider Buying and Selling for Chembio Diagnostics.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $5.76.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $101.20 million and generates $33.41 million in revenue each year. The company earns $-7,870,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Chembio Diagnostics employs 295 workers across the globe.View Additional Information About Chembio Diagnostics.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is http://www.chembio.com/.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]


MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel